Resonetics closes Resolution Medical deal, targeting full-stack dominance in neuromodulation and structural heart

Resonetics, the Nashua, New Hampshire-based medical device contract development and manufacturing organisation backed by private equity firms Carlyle (NASDAQ: CG) and GTCR, has completed its acquisition of Resolution Medical, a Fridley, Minnesota-headquartered contract manufacturer of complex Class II and III medical devices. The deal, first announced in January 2026, adds Resolution Medical’s biosimulation laboratories, design engineering capabilities, new product introduction processes, and ISO cleanroom assembly operations to Resonetics’ existing platform of precision component manufacturing, advanced materials, nitinol processing, and implantable battery technologies. For Resonetics, the transaction closes a significant gap in its service offering: the ability to take an OEM customer’s concept all the way from early engineering and simulation through to finished device assembly and scaled commercial production, without handoffs to outside parties. The combined organisation now stands as one of the more comprehensively integrated medtech contract development and manufacturing platforms in North America.

Why Resonetics acquiring Resolution Medical changes the medtech CDMO landscape for neuromodulation OEMs

The strategic logic here is not simply about scale. Resonetics had long been recognised as a precision component manufacturer of the first order, its capabilities in nitinol processing, laser micro-manufacturing, and implantable battery production placing it at the upstream end of the medtech supply chain. What it lacked was front-end design authority. Resolution Medical fills that gap directly. Resolution Medical’s biosimulation capability, which recreates in-vivo conditions to test and refine device behaviour without relying exclusively on animal models, is a meaningful differentiator for OEM customers navigating increasingly demanding regulatory pathways for structural heart and neuromodulation therapies. The integration of biosimulation with Resonetics’ AGILE Product Development group creates a combined development environment that can compress the time between concept and clinical prototype, a pain point for every device company operating in markets where first-mover advantage translates directly into market share.

Resolution Medical brings more than 240 employees to the combined organisation, including over 100 engineers, along with operations in the Netherlands that extend Resonetics’ geographic footprint into Western Europe. The Netherlands presence is not incidental given the concentration of structural heart and interventional cardiology innovation in that region, including proximity to major OEM customers and academic medical centres with active device development programmes. For Resonetics, absorbing European engineering capability alongside US cleanroom manufacturing adds optionality in how it structures programmes for multinational OEM clients.

How the Resolution Medical acquisition fits into Resonetics’ accelerating acquisition strategy since 2025

The Resolution Medical close is the latest in a sequence of targeted acquisitions that Resonetics has executed at pace over the past several months. In January 2026, Resonetics acquired manufacturing assets and process intellectual property related to implantable and external pulse generator production from Med-Ally, adding IPG and EPG capabilities to its Medical Power business. In September 2025, the company absorbed Eden Holdings, adding precision injection molding and micro-machining solutions to its materials portfolio. Each acquisition has followed a recognisable pattern: identify a capability gap that OEM customers are managing through external relationships, acquire the organisation that fills it, and integrate it into the Resonetics platform to capture more of the customer’s programme value.

The deliberateness of this sequencing matters. The Med-Ally assets anchored the energy source end of an active implantable device. Resolution Medical’s finished device and sub-assembly capabilities anchor the integration end. Together with Resonetics’ precision component manufacturing in between, the company can now credibly position itself as a single-source partner across the full device lifecycle for neuromodulation programmes, covering battery, lead, pulse generator, and finished device assembly within one contracted relationship. That is a materially different proposition from what any individual predecessor business could have offered.

What the integration of biosimulation and cleanroom assembly means for structural heart device development timelines

Structural heart is one of the highest-value therapeutic categories in medtech, characterised by complex device geometries, demanding regulatory requirements, and long development cycles. The combination of Resolution Medical’s biosimulation laboratories with Resonetics’ nitinol processing and catheter manufacturing capabilities creates an integrated development environment that addresses a genuine bottleneck in how structural heart devices progress from concept to first-in-human use. Biosimulation facilities that replicate haemodynamic conditions can validate design assumptions earlier in the development process, reducing the number of costly design iterations and regulatory submissions required before clinical work begins.

Resolution Medical’s existing customer relationships in structural heart also carry significant value. The company had built its reputation working with OEM customers on advanced catheter delivery systems, nitinol stent components, and guidewires, product categories where Resonetics was already an established manufacturer. The overlap between Resolution Medical’s customer base and Resonetics’ existing relationships creates both cross-selling opportunity and the potential for deeper programme integration for shared customers, though capturing that value will require careful account management to avoid disrupting relationships that Resolution Medical has built independently under Arcline Investment Management’s ownership.

How does Resonetics’ integrated platform compare to Integer Holdings and other medtech contract manufacturers in 2026

The medtech contract development and manufacturing sector has been consolidating steadily as OEMs face increasing device complexity and seek to reduce the number of suppliers managing different parts of their programmes. Integer Holdings (NYSE: ITGR), which operates across cardiac rhythm management, neuromodulation, and vascular segments, is the most direct publicly traded comparable for the Resonetics platform. Integer’s scale remains substantially larger, but its model has historically tilted towards high-volume component manufacturing rather than the full-lifecycle development-through-production model that Resonetics is assembling. The completion of the Resolution Medical acquisition accelerates Resonetics’ movement into the design and development phase of the customer relationship, which Integer has addressed less aggressively.

Seisa Medical and smaller specialists such as Cadence remain present in discrete segments of the medtech supply chain, but the breadth of capabilities that Resonetics is assembling is creating meaningful distance from single-capability competitors. The more interesting competitive question is how large OEM customers respond to a CDMO that can legitimately take on ownership of an entire programme. Some OEMs will welcome the consolidation and the reduction in programme management overhead it implies. Others, particularly larger device companies with established internal engineering organisations, may prefer to retain design control and use Resonetics selectively for manufacturing execution rather than end-to-end engagement. The answer will shape how the Resonetics revenue model develops over the next several years.

What are the execution risks in integrating Resolution Medical’s engineering culture into Resonetics’ manufacturing platform

Integrating an engineering-led design organisation into a manufacturing-centric platform carries recognisable risks. Resolution Medical’s competitive advantage has rested substantially on the engineering responsiveness and technical depth it provided to customers, attributes that are function of talent retention and organisational culture as much as physical infrastructure. Resonetics has framed the acquisition as an opportunity to extend Resolution Medical’s capabilities with broader manufacturing resources, but the integration process itself can disrupt the engineering team dynamics that made Resolution Medical attractive to its OEM customers in the first place. The departure of even a handful of senior engineers in specialised areas like biosimulation or active implantable device design would represent a disproportionate loss relative to headcount.

Resonetics’ track record on integration across its prior acquisitions, including Eden Holdings and the Med-Ally assets, provides some reassurance that the company understands these risks. The stated approach of maintaining Resolution Medical’s existing customer teams and engineering identity within the larger platform is consistent with best practice for talent-dependent acquisitions. The test will come over the next twelve to eighteen months as customers evaluate whether the combined entity’s programme execution holds the standard they had come to expect from Resolution Medical as a standalone business.

What the Carlyle and GTCR-backed Resonetics platform signals about private equity strategy in medtech manufacturing M&A

Carlyle entered Resonetics in 2021 at an implied valuation of approximately $2.25 billion, joining GTCR which had owned the business since 2018. Since that recapitalisation, the acquisition pace has accelerated markedly, with Eden Holdings, Med-Ally assets, and now Resolution Medical closing within a twelve-month window. The strategy is recognisably a platform build, assembling capability adjacencies to increase the total addressable revenue per OEM customer relationship rather than simply growing the component manufacturing business organically. For Carlyle, which manages approximately $477 billion in assets under management, Resonetics represents a thesis around the structural shift in medtech supply chains toward more outsourced, integrated development and manufacturing partnerships.

Arcline Investment Management, which sold Resolution Medical in this transaction, had acquired the business as a standalone engineering services and manufacturing organisation focused on complex Class II and III device categories. Under Arcline’s ownership, Resolution Medical had expanded its capabilities and developed deeper customer relationships in neuromodulation and structural heart. The sale to Resonetics represents a conventional PE exit path for Arcline, enabling it to realise value from the platform it built while Resolution Medical gains access to the manufacturing scale and technology breadth needed to compete for larger, more integrated programme opportunities.

Key takeaways: What the Resonetics and Resolution Medical deal means for medtech manufacturing strategy in 2026

• Resonetics has completed the acquisition of Resolution Medical, adding biosimulation, design engineering, new product introduction, and cleanroom finished device assembly to its platform of precision component manufacturing, nitinol processing, and implantable battery technologies.
• The deal closes what had been a meaningful gap in Resonetics’ service offering: the capacity to serve OEM customers from early concept development all the way through to commercial-scale finished device production within a single contracted relationship.
• Resolution Medical’s biosimulation capability, which recreates in-vivo conditions to test device designs, is a differentiator for structural heart and neuromodulation OEMs navigating complex regulatory pathways and seeking to compress development timelines.
• The acquisition follows the January 2026 purchase of IPG and EPG manufacturing assets from Med-Ally and the September 2025 acquisition of Eden Holdings, reflecting an accelerating roll-up strategy that is systematically closing capability gaps across the full device lifecycle.
• Resolution Medical’s Netherlands operations extend Resonetics’ geographic footprint into Western Europe, adding proximity to structural heart and interventional cardiology OEM customers and innovation centres in that region.
• For competitors such as Integer Holdings, the Resonetics platform build represents a strategic shift in the competitive landscape of medtech contract manufacturing, with an integrated design-through-production model potentially displacing multi-vendor approaches that OEMs have historically relied upon.
• Integration risk is the primary near-term execution concern. Resolution Medical’s value to customers has rested substantially on engineering responsiveness and biosimulation expertise that is talent-dependent, and retaining key technical staff through the integration process will be critical.
• Carlyle and GTCR’s continued capital deployment into Resonetics reflects a private equity thesis around the structural shift in medtech supply chains toward outsourced, integrated development and manufacturing partnerships, a theme likely to drive further consolidation in the sector.
• Financial terms of the Resolution Medical acquisition have not been disclosed, leaving the transaction’s implied multiple and its contribution to Resonetics’ overall leverage profile unquantifiable from public information.
• The combined organisation’s ability to demonstrate programme execution continuity for Resolution Medical’s existing structural heart and neuromodulation customers over the next twelve to eighteen months will be the primary indicator of whether the strategic rationale translates into durable revenue.